First Data from MZL Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel) Presented June 24, 2025
Positive Ph 2 interim results in R/R indolent NHL after EO2463 OncoMimics immunotherapy treatment presented June 24, 2025
Positive New Clinical Data Demonstrating High Rates of Durable CRs from the Ph 1/2 Trial of LYL314 in Aggressive Large B-cell Lymphoma Announced June 24, 2025
Lunsumio and Polivy Combination Significantly Prolongs Remission for People With R/R Large B-Cell Lymphoma June 24, 2025
Ph 3 KEYNOTE-B96 Trial Met PFS Primary Endpoint in Platinum-Resistant Recurrent Ovarian Cancer Patients Whose Tumors Expressed PD-L1 and in All Comers June 17, 2025
FAILED TRIAL: Ph 3 VERONA of venetoclax + azacitidine in 1L higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of OS June 17, 2025
Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years upon treatment with the INB-200 in GBM trial June 17, 2025
Results from Ph 1/2 Study of Sacituzumab Tirumotecan (sac-TMT) in Solid Tumors Refractory to Standard Therapies Published in Journal of Hematology & Oncology June 17, 2025
Ph 3 Data for Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet June 17, 2025
AKEEGA® (niraparib and abiraterone acetate dual-action tablet) improved efficacy in patients with HRR-mutated mHSPC vs. current SoC June 11, 2025
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95% PFS at four years in transplant-eligible 1L multiple myeloma patients who achieved sustained MRD negativity June 10, 2025
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in RRMM patients June 10, 2025
BMJ Publishes results from OptiTROP-Lung03 trial of sacituzumab tirumotecan (sac-TMT) vs docetaxel in patients with previously treated EGFR-mutant NSCLC June 10, 2025
Positive Topline Efficacy Results Reported from Ph 1B/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Mets (MB-107) June 10, 2025
Efti with Radiotherapy & KEYTRUDA Meets Primary Endpoint in Ph 2 for Soft Tissue Sarcoma June 3, 2025
Ivonescimab + Chemo Demonstrates Statistically Significant PFS Improvement and numerical OS improvement in topline data in EGFRm NSCLC after EGFR TKI June 3, 2025
Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA+ve metastatic HSPC June 3, 2025
Positive Results from Ph 3 TALENTACE Study of Tecentriq and Avastin for Unresectable HCC announced May 27, 2025
Trodelvy Demonstrates Significant PFS Improvement in 1L Metastatic TNBC Patients Not Candidates for Checkpoint Inhibitors in ASCENT-03 trial May 27, 2025